Conducted: Ames, human lymphocyte chromosome aberration, rat micronucleus; all negative
“Givosiran was not mutagenic in the in vitro bacterial reverse mutation test or clastogenic in the in vitro chromosomal aberrations assay in human peripheral blood lymphocytes or in the in vivo bone marrow micronucleus assay in rats.”
✓ VerifiedFDA multi-discipline review, p. 28Source ↗
Carcinogenicity
Conducted: 26-week Tg.rasH2 mouse negative; 2-year rat (post-approval) showed hepatocellular adenomas in males at 100 mg/kg
“A statistically significant increase in hepatocellular adenomas occurred in males at 100 mg/kg/month, the clinical significance of which is uncertain.”
Full DART: rat fertility/EFD, rabbit EFD (postimplantation loss with maternal toxicity), rat PPND; no malformations
“Givosiran showed marked maternal toxicity in rabbits (including mean maternal body weight loss) and resulted in increased post-implantation loss as a result of increased early resorptions and a low incidence of skeletal variations.”
Standalone GLP CV/respiratory telemetry study in monkey (single 150 mg/kg SC); no clear effects
“A safety pharmacology study assessed the effects of a single subcutaneous dose of 150 mg/kg givosiran on cardiovascular and respiratory function in male telemetered cynomolgus monkeys.”
✓ VerifiedFDA multi-discipline review, p. 26Source ↗